121.90
price up icon1.03%   1.24
after-market After Hours: 121.96 0.06 +0.05%
loading
Sarepta Therapeutics Inc stock is traded at $121.90, with a volume of 204.55K. It is up +1.03% in the last 24 hours and up +6.71% over the past month. Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
See More
Previous Close:
$120.66
Open:
$120.21
24h Volume:
204.55K
Relative Volume:
0.22
Market Cap:
$11.64B
Revenue:
$1.64B
Net Income/Loss:
$121.85M
P/E Ratio:
-15.57
EPS:
-7.83
Net Cash Flow:
$-480.40M
1W Performance:
-3.07%
1M Performance:
+6.71%
6M Performance:
-25.60%
1Y Performance:
+28.94%
1-Day Range:
Value
$120.00
$122.18
1-Week Range:
Value
$117.39
$126.04
52-Week Range:
Value
$91.34
$173.25

Sarepta Therapeutics Inc Stock (SRPT) Company Profile

Name
Name
Sarepta Therapeutics Inc
Name
Phone
617-274-4000
Name
Address
215 FIRST STREET, CAMBRIDGE, MA
Name
Employee
1,314
Name
Twitter
@sarepta
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
SRPT's Discussions on Twitter

Compare SRPT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SRPT
Sarepta Therapeutics Inc
121.90 11.64B 1.64B 121.85M -480.40M 1.54
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
408.18 105.12B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
714.47 78.51B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
629.99 37.67B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
243.25 31.37B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
114.13 27.36B 3.30B -501.07M 1.03B -2.1146

Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-27-24 Reiterated Needham Buy
Nov-25-24 Initiated H.C. Wainwright Sell
Nov-07-24 Upgrade Cantor Fitzgerald Neutral → Overweight
Oct-21-24 Initiated Jefferies Buy
Oct-10-24 Resumed Raymond James Outperform
Jul-29-24 Upgrade RBC Capital Mkts Sector Perform → Outperform
Jun-26-24 Downgrade Citigroup Buy → Neutral
May-31-24 Initiated Piper Sandler Overweight
May-28-24 Downgrade RBC Capital Mkts Outperform → Sector Perform
May-14-24 Upgrade Oppenheimer Perform → Outperform
Jan-31-24 Initiated BMO Capital Markets Outperform
Dec-13-23 Resumed Citigroup Buy
Dec-12-23 Initiated Deutsche Bank Buy
Nov-21-23 Initiated Wedbush Outperform
Oct-31-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Oct-31-23 Downgrade Oppenheimer Outperform → Perform
Jun-23-23 Downgrade Evercore ISI Outperform → In-line
Apr-26-23 Initiated SMBC Nikko Outperform
Apr-04-23 Initiated Citigroup Buy
Mar-01-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-22-22 Reiterated BTIG Research Buy
Dec-16-22 Upgrade UBS Neutral → Buy
Apr-04-22 Resumed Cantor Fitzgerald Overweight
Jan-05-22 Reiterated Needham Buy
Dec-09-21 Upgrade Oppenheimer Perform → Outperform
Nov-05-21 Upgrade JP Morgan Neutral → Overweight
Sep-15-21 Upgrade Guggenheim Neutral → Buy
Aug-05-21 Upgrade JP Morgan Underweight → Neutral
Jun-15-21 Initiated BTIG Research Buy
Apr-26-21 Resumed Credit Suisse Neutral
Jan-12-21 Downgrade Citigroup Buy → Neutral
Jan-11-21 Downgrade UBS Buy → Neutral
Jan-08-21 Downgrade JP Morgan Overweight → Underweight
Jan-08-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Jan-08-21 Downgrade Raymond James Outperform → Mkt Perform
Nov-11-20 Initiated Berenberg Hold
Oct-28-20 Initiated UBS Buy
Aug-25-20 Initiated Raymond James Outperform
Aug-20-20 Downgrade Credit Suisse Outperform → Neutral
Mar-31-20 Initiated Mizuho Buy
Nov-01-19 Initiated Guggenheim Buy
Aug-21-19 Reiterated Needham Buy
Jul-09-19 Reiterated Morgan Stanley Overweight
Jul-01-19 Reiterated RBC Capital Mkts Outperform
Apr-12-19 Initiated Evercore ISI Outperform
Mar-11-19 Reiterated Credit Suisse Outperform
Oct-12-18 Initiated Bernstein Outperform
Oct-01-18 Initiated Cantor Fitzgerald Overweight
Sep-26-18 Reiterated RBC Capital Mkts Outperform
Sep-14-18 Resumed BofA/Merrill Buy
Sep-06-18 Initiated Credit Suisse Outperform
Aug-01-18 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-21-18 Reiterated Robert W. Baird Outperform
Jun-20-18 Reiterated Needham Buy
Jun-19-18 Reiterated H.C. Wainwright Buy
View All

Sarepta Therapeutics Inc Stock (SRPT) Latest News

pulisher
Dec 23, 2024

Is Sarepta Therapeutics, Inc. (SRPT) the Best Performing Biotech Stock in 2024? - Insider Monkey

Dec 23, 2024
pulisher
Dec 20, 2024

Nippon Owes $115M In Muscular Dystrophy IP Fight, Jury Says - Law360

Dec 20, 2024
pulisher
Dec 20, 2024

Nippon Shinyaku Owes Sarepta $115 Million in Patent Verdict (1) - Bloomberg Law

Dec 20, 2024
pulisher
Dec 20, 2024

Sarepta Wins First Phase of Nippon Shinyaku Gene-Therapy Trial - Bloomberg Law

Dec 20, 2024
pulisher
Dec 20, 2024

SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder - MSN

Dec 20, 2024
pulisher
Dec 20, 2024

The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam - Yahoo Finance

Dec 20, 2024
pulisher
Dec 19, 2024

Communiqué de presse - GlobeNewswire Inc.

Dec 19, 2024
pulisher
Dec 19, 2024

Sarepta completes subject dosing in Phase III LGMD2E/R4 therapy trial - Yahoo Finance

Dec 19, 2024
pulisher
Dec 19, 2024

Sarepta Therapeutics (NASDAQ:SRPT) Receives Sell Rating from HC Wainwright - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 15 Analysts - Benzinga

Dec 19, 2024
pulisher
Dec 19, 2024

Even though Sarepta Therapeutics (NASDAQ:SRPT) has lost US$491m market cap in last 7 days, shareholders are still up 33% over 1 year - Simply Wall St

Dec 19, 2024
pulisher
Dec 18, 2024

Sarepta Completes Pivotal Phase 3 Trial Enrollment for Groundbreaking Muscular Dystrophy Gene Therapy - StockTitan

Dec 18, 2024
pulisher
Dec 18, 2024

National Bank of Canada FI Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Dec 18, 2024
pulisher
Dec 17, 2024

3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025 - Yahoo Finance

Dec 17, 2024
pulisher
Dec 16, 2024

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Sells $1,310,820.00 in Stock - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Geode Capital Management LLC Has $211.91 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Stifel Financial Corp Grows Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Sarepta Therapeutics' SWOT analysis: DMD leader's stock poised for growth - Investing.com

Dec 16, 2024
pulisher
Dec 15, 2024

19,358 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Bought by World Investment Advisors LLC - MarketBeat

Dec 15, 2024
pulisher
Dec 14, 2024

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Yahoo Finance

Dec 14, 2024
pulisher
Dec 14, 2024

Garden State Investment Advisory Services LLC Buys Shares of 16,936 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Dec 14, 2024
pulisher
Dec 13, 2024

Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst - Benzinga

Dec 13, 2024
pulisher
Dec 13, 2024

FDA’s new accelerated approval guidance to benefit rare disease drug development, analysts believe - Proactive Investors USA

Dec 13, 2024
pulisher
Dec 13, 2024

Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High? - Yahoo Finance

Dec 13, 2024
pulisher
Dec 13, 2024

Y Intercept Hong Kong Ltd Sells 29,809 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Dec 13, 2024
pulisher
Dec 11, 2024

HighTower Advisors LLC Sells 10,327 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Dec 11, 2024
pulisher
Dec 09, 2024

Two Sigma Advisers LP Lowers Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Dec 09, 2024
pulisher
Dec 09, 2024

Point72 Asset Management L.P. Cuts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Dec 09, 2024
pulisher
Dec 08, 2024

Main Management ETF Advisors LLC Makes New Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Dec 08, 2024
pulisher
Dec 08, 2024

Wellington Management Group LLP Purchases 665,087 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Dec 08, 2024
pulisher
Dec 07, 2024

Kathryn Jean Boor Sells 1,636 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock - MarketBeat

Dec 07, 2024
pulisher
Dec 07, 2024

Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report? - MSN

Dec 07, 2024
pulisher
Dec 07, 2024

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Dec 07, 2024
pulisher
Dec 06, 2024

Sarepta therapeutics director sells $205,399 in stock - Investing.com India

Dec 06, 2024
pulisher
Dec 06, 2024

Sarepta therapeutics director sells $205,399 in stock By Investing.com - Investing.com Nigeria

Dec 06, 2024
pulisher
Dec 06, 2024

Stock Market Movers Today • Top Gainers & Losers - Benzinga

Dec 06, 2024
pulisher
Dec 06, 2024

Soros Fund Management LLC Acquires Shares of 206,583 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Dec 06, 2024
pulisher
Dec 05, 2024

Duchenne Muscular Dystrophy Pipeline Insights 2024: - openPR

Dec 05, 2024
pulisher
Dec 05, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 33,278 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Dec 05, 2024
pulisher
Dec 04, 2024

Sarepta, Biotech’s Regulatory Go-Getter, Signs Standout Rare Disease Deal - BioSpace

Dec 04, 2024
pulisher
Dec 04, 2024

The Manufacturers Life Insurance Company Has $9.34 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Dec 04, 2024
pulisher
Dec 03, 2024

Sarepta to develop Arrowhead’s muscular dystrophy treatments - Muscular Dystrophy News

Dec 03, 2024
pulisher
Dec 03, 2024

ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing… - MSN

Dec 03, 2024
pulisher
Dec 03, 2024

Sarepta gains rights to Arrowhead Huntington’s treatment candidate - Huntington's Disease News

Dec 03, 2024
pulisher
Dec 03, 2024

Sarepta Therapeutics' SWOT analysis: gene therapy leader's stock poised for growth - Investing.com

Dec 03, 2024
pulisher
Dec 03, 2024

Edgestream Partners L.P. Takes $2.31 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Dec 03, 2024
pulisher
Dec 02, 2024

Zacks Research Has Positive Forecast for SRPT Q1 Earnings - MarketBeat

Dec 02, 2024
pulisher
Dec 01, 2024

Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio? - Benzinga

Dec 01, 2024
pulisher
Dec 01, 2024

Erste Asset Management GmbH Purchases Shares of 636,065 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Dec 01, 2024
pulisher
Dec 01, 2024

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Bellevue Group AG - MarketBeat

Dec 01, 2024
pulisher
Dec 01, 2024

Point72 Europe London LLP Invests $872,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Dec 01, 2024

Sarepta Therapeutics Inc Stock (SRPT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$69.91
price up icon 0.10%
$19.00
price up icon 1.77%
$40.27
price up icon 1.72%
$360.87
price down icon 0.76%
$181.62
price up icon 2.21%
$114.13
price up icon 0.55%
Cap:     |  Volume (24h):